The Department of Health (DOH) posted an advisory on its DOH FB page last May 30, 2025, informing the public of its approval for the temporary suspension of FDA New Regulatory Fees. The approved FDA memorandum with Subject: Recommendation to temporarily suspend the implementation of Administrative Order 2024-0016: Implementing Guidelines on the New Schedule of Fees and Charges of the Food and Drug Administration, was signed by the DOH Secretary, Teodoro J. Herbosa, MD.
The suspension would take effect seven (7) days after approval by the DOH Secretary as stated in the FDA press release last 29 May 2025, and would remain in force for sixty (60) days.
The suspension seeks to allow time for a comprehensive review of specific provisions of the AO in coordination with the relevant FDA Centers.
Implications to Stakeholders
Stakeholders may experience temporary relief from the increased regulatory fees under AO No. 2024-0016.
Effectivity
Seven (7) days post-approval.
View full press release here: https://www.facebook.com/share/18rZSyzpva/
View full advisory here: https://www.facebook.com/share/p/14M4Keac9Bc/?mibextid=wwXIfr
For more information or assistance, contact us at sales@andamanmed.com or click the button below.
